कंपनी का अवलोकन
Fortress Biotech, Inc. operates as a biopharmaceutical entity focused on the development and commercialization of specialized biopharmaceutical products, with a specific emphasis on dermatology solutions. The company functions within the healthcare sector and the biotechnology industry, where innovation in drug formulation and therapeutic delivery is critical for addressing unmet medical needs. Fortress Biotech, Inc. currently holds a market capitalization of $77.29M and generates annual revenue of $63.26M, though specific employee count data is unavailable in the provided records. These valuation and revenue figures indicate that the company occupies a mid-tier position within the biotechnology landscape, suggesting a scale sufficient for commercialization activities yet remaining relatively small compared to large-cap pharmaceutical peers. The limited workforce data combined with a market cap under $100 million suggests the organization relies on lean operational structures typical of companies in the growth phase of the biotechnology value chain.
वित्तीय स्वास्थ्य
Fortress Biotech, Inc. reported a revenue of $63.26M over the trailing twelve months, while recording a net income of $-1,882,000 and an EBITDA of $-65,560,000. The significant divergence between the positive revenue figure and the negative net income reveals a cost structure where operating expenses substantially exceed gross profits, a common characteristic in the early commercialization stages of biotechnology firms. The company maintains a free cash flow of $-47,286,376, which indicates a net outflow of cash required to fund ongoing research, development, and commercialization efforts rather than generating distributable surplus. Regarding profitability metrics, the gross margin stands at 48.1%, indicating that the company retains nearly half of its revenue after direct production costs. However, the operating margin is negative at -29.8%, reflecting high overhead costs associated with R&D and administrative functions, while the profit margin shows a positive 10.8%, likely influenced by specific accounting treatments or non-operating income items. The balance sheet shows a cash position of $79.38M against total debt of $67.22M, resulting in a debt-to-equity ratio of 108.09. This leverage profile suggests the company utilizes significant debt financing relative to its equity base, which increases financial risk but also amplifies potential returns if profitability improves. The current ratio of 2.49 demonstrates strong short-term liquidity, indicating that the company possesses more than twice the current assets necessary to cover its current liabilities without immediate distress. Return on Equity stands at -108.7% and Return on Assets at -26.6%, metrics that reveal management is currently consuming rather than generating returns on the capital invested, consistent with a company burning cash to achieve future product milestones.
मूल्यांकन आकलन
The valuation metrics for Fortress Biotech, Inc. show a P/E Ratio (TTM) listed as N/A due to negative earnings, while the forward P/E is -1.36. The absence of a trailing P/E and the negative forward multiple imply that the market is pricing the stock based on future potential rather than current profitability, as traditional earnings-based valuation models are not applicable in the short term. The price-to-book ratio is 1.33, which indicates that the market values the company at 33% above its book value, suggesting investors are willing to pay a premium for the intangible assets and potential of the pharmaceutical pipeline. Alternative valuation measures include a price-to-sales ratio of 1.22 and an EV/EBITDA of -1.18, which suggest the stock is trading at a valuation slightly above its sales multiple but remains deeply negative on an earnings basis. In terms of trading range, the 52-week high is $4.53 and the 52-week low is $1.33, meaning the current price sits significantly below the recent peak, reflecting the recent market volatility often seen in biotechnology stocks. The beta value is 1.45, indicating that the stock's price volatility is 45% higher than the broader market, making it a high-risk instrument sensitive to sector-specific news and interest rate changes.
Growth & Income
Fortress Biotech, Inc. experienced a revenue growth of 6.3% year-over-year, whereas earnings growth is listed as N/A due to negative net income. Since earnings are negative, they cannot grow faster than revenue in the traditional sense, implying the company is still in a phase where revenue expansion does not yet translate to bottom-line profitability. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%. Consequently, the company reinvests all available earnings and cash reserves directly back into growth initiatives such as clinical trials and product development rather than distributing income to shareholders. This profile characterizes Fortress Biotech, Inc. as a non-income stock where returns for shareholders depend entirely on the successful commercialization of future products and the eventual restoration of profitability rather than current cash distributions.